Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02596737
Other study ID # CHU-0247
Secondary ID
Status Recruiting
Phase N/A
First received October 15, 2015
Last updated November 3, 2015
Start date May 2015
Est. completion date October 2018

Study information

Verified date November 2015
Source University Hospital, Clermont-Ferrand
Contact Patrick LACARIN
Phone 04 73 75 11 95
Email placarin@chu-clermontferrand.fr
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertés
Study type Interventional

Clinical Trial Summary

Individuals spend one third of their life working. Age of retirement is regularly pushed back. The main challenge in the nearest future will be to maintain workers health to deal with their work till retirement. Morbidity before retirement has a huge cost, both in public health and economically for companies. Numerous factors increase morbidity such as stress at work, sedentary and low physical activity, and poor nutrition habits. Nowadays, digital world wildly invades lives and offer a no-limit possibility to interact with individuals, everywhere. Thus, a software able to understand an individual in its globality seems to address this challenge. Moreover, managers need to understand the actions needed within their company. The objective of WittyFit is to increase life expectancy and well-being. WittyFit will constitute a powerful database to build strong evidence and new knowledge on the relationships between work, behavior, and health, based on a large amount of epidemiological data.


Description:

1. Whereas other interventional software focus on a specific aim (relaxation, musculo-skeletal disorder, etc), Wittyfit has the ambition to promote health with a global understanding of workers, based on continuous and updated scientific knowledge (evidence based medicine). A feedback is given on targets screened from questionnaires through e-learning and personalized motivating messages.

2. The second novelty of WittyFit is that managers will also have an anonymous feedback on the general state of health and problems encountered by its employees, in general or by department if the sample size is sufficiently high. Managers will indeed be able to target specific actions such as promoting physical activity at work or helping its employees to quit smoking.

3. Third, WittyFit is a prevention tool in collaboration with occupational medicine, which may help to detect a high risk toward the integrity of an employee.

4. Moreover, WittyFit is in fact based on two databases: "WittyFit" which deals with behavioral data, and "WittyFit Research" which deals with medical data. To guarantee the highest level of security, the two databases are separate and do not communicate together; physicians from the CHU of Clermont-Ferrand will be the only individuals with an access to medical data.

5. When a worker will leave Wittyfit, the company will encode three possibilities: retirement, move for another company, or premature death. Therefore, WittyFit will have the ability to have mortality as a primary outcome.

6. Finally, WittyFit may constitute a powerful database to build strong evidence and new knowledge on the relationships between lifestyle and health, based on huge amount of epidemiological data.

7. At last, WittyFit will evolve with the waves of connected objects further increasing its data accuracy, with the use of devices such as pedometers, heart rate monitors, accelerometers, thermometer, etc.

8. WittyFit is building a rainbow: work (shiftwork, sedentary job, particular occupations, etc) / psychology and physiology / statistics modeling / public health, and in general, health.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date October 2018
Est. primary completion date October 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- All workers who want to participate to the WittyFit concept will be included.

Exclusion Criteria:

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Behavioral:
wittyFit concept


Locations

Country Name City State
France CHU Clermont-Ferrand Clermont-Ferrand

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand Australian Catholic University, WittyFit

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary all cause mortality When a worker will leave Wittyfit, the company will encode three possibilities: retirement, move for another company, or premature death. every year, up to 10 years No
Secondary visual analog scale of physical well-being However individuals will be able to spontaneously complete this data more frequently every 15 days, up to 10 years No
Secondary visual analog scale of mental well-being however individuals will be able to spontaneously complete this data more frequently every 15 days, up to 10 years No
Secondary visual analog scale of well-being at-work however individuals will be able to spontaneously complete this data more frequently every 15 days, up to 10 years No
Secondary Nutritional intake measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary Physical activity measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary Sleep measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary Musculo-skeletal disorders measured by questionnaire Every participant can fulfil questionnaires when he wants. however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary Hospital and Anxiety Depression Scale however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary Stress and Mood measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary job strain measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary latitude decision measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary work organization and tasks measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary social support measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary recognition measured by questionnaire however individuals will be able to spontaneously complete this data more frequently every 6 months, up to 10 years No
Secondary disease and medical history measured by questionnaire every 12 months, up to 10 years No
Secondary routine medications measured by questionnaire every 12 months, up to 10 years No
Secondary number of days of sick leave provided by the employer every 12 months, up to 10 years No
Secondary sales turnover of the company, provided by the employer every 12 months, up to 10 years No
Secondary net income or net gain of the company, provided by the employer every 12 months, up to 10 years No
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04092465 - Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT)
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Completed NCT04149873 - Effectness of Treatment With Mechanical Insufflation-Exsufflation N/A
Completed NCT05905042 - Follow-up of Recovery Condition in Survivors of Acute Respiratory Distress Syndrome
Completed NCT00527774 - Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients N/A
Completed NCT00518856 - Lufwanyama Neonatal Survival Project N/A
Completed NCT06408636 - Prognostic Role of LA Strain in Acute Myocardial Infarction
Completed NCT06051526 - The African Critical Illness Outcomes Study
Recruiting NCT05055089 - Short- and Medium-term Results of New Generation Aortic
Active, not recruiting NCT04132492 - AGNES - Aging Nephropathy Study, a Prospective Observational Cohort of Chronic Kidney Disease in Elderly Patients
Completed NCT03885206 - Effectiveness and Clinical Outcomes of Municipal Acute Wards Versus a General Hospital N/A
Completed NCT05573659 - Capillary Refill Time Calculated With a Video-assisted Method Has a Better Reproducibility Than Visual Method in Critically Ill Patients N/A
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Recruiting NCT04094428 - Burden, Mortality and Supply Costs in Intensive Care Unit Patients
Completed NCT01631799 - Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia N/A
Completed NCT00244673 - Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Phase 4
Completed NCT03378843 - Spermidine Intake and All-cause Mortality N/A
Recruiting NCT04424511 - Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali Phase 3